Cardiac Insight, a specialist in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, has announced that researchers at Stanford Medicine selected the company’s Cardea SOLO wearable ECG system for a medical study entitled: ‘Serial 7-Day electrocardiogram patch screening for atrial fibrillation in high-risk older women by the CHARGE-AF score’.
The study set out to measure asymptomatic atrial fibrillation (AF) in older women since AF is associated with an increased risk of stroke. The researchers wanted to determine the frequency of AF detected by serial, seven-day ECG patch screenings from patients identified as having an elevated risk of AF. The participants were sent a Cardea ECG patch monitor to be worn for seven days and returned for analysis.
Cardea SOLO is a lightweight, water-resistant ambulatory cardiac monitoring system. The wearable ECG sensor provides exceptionally accurate results using Cardia Insight’s automated ECG data analysis and reporting software.
“We are delighted that the research team elected to standardise on Cardea SOLO for their study,” said Min Kim, chief executive officer of Cardiac Insight. “In this kind of research, it is essential to have reliable, accurate results. We are proud of the sensitivity and accuracy of our wearable ECG monitoring system as we designed Cardea SOLO for in-office diagnostic procedures, so extracting patient data is easy and safe.”